Advertise on podcast: Melanoma Insights for Professionals

As patients transition from treatment to routine monitoring, clinicians play a crucial part in detecting recurrence early, supporting wellbeing, and guiding patients through survivorship. In the latest episode of our podcast Melanoma Insights for Professionals, we explore the essential role of follow-up care in melanoma management. Our multidisciplinary experts provide an engaging and practical discussion to help strengthen your approach to melanoma follow-up care and covers: why follow-up schedules vary and how clinicians tailor them stage-specific approaches for all stages of melanoma the role of dermatological surveillance and patient education supporting psychological wellbeing, including managing scanxiety. This podcast is suitable for Surgeons, Dermatologists, Skin Cancer GPs, GPs, Nurses and other health professionals. If you require a Statement of Completion for your CPD records, please listen to this podcast via the the Melanoma Education Portal. SPEAKERS A/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of SydneyDr Mary-Ann El Sharouni - Dermatologist, Melanoma Institute Australia and Sydney Melanoma Diagnostic Centre, Royal Prince Alfred HospitalClaire Gore - Senior Clinical Psychologist, Melanoma Institute Australia RESOURCES MIA’s Patient Resources (including Guides like Melanoma Prevention and Early Detection Guide and Patient Fact Sheet such as Scanxiety and How to cope with the fear of melanoma returning)Cancer Council’s SunSmart Global UV app Please note that this presentation was accurate at the time of recording (November 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

As melanoma in situ (MIS) diagnoses rise, concerns about overdiagnosis are growing — with real implications for patients, clinicians and the health system. In this episode of our podcast Melanoma Insights for Professionals, experts from dermatology, pathology, psychology and research come together to explore the drivers of overdiagnosis, the psychological impact of an MIS label, and the role of emerging diagnostic tools and data. This podcast is suitable for multidisciplinary specialist, primary care physicians and other healthcare professionals. SPEAKERS Dr Peter Ferguson - Pathologist, Royal Prince Alfred Hospital and Melanoma Institute AustraliaDr Christoph Sinz - Confocal Microscopy Dermatologist, Melanoma Institute AustraliaClaire Gore - Senior Clinical Psychologist, Melanoma Institute AustraliaDr Ismael Vergara - Senior Computational Biologist, Melanoma Institute Australia | Adjunct Senior Lecturer, The University of Sydney RESOURCES MIA’s Patient Guides (e.g. Your Guide to Melanoma In-Situ) MIA’s Patient Fact Sheets (e.g. Scanxiety) REFERENCES Bjørch MF, Gram EG, Brodersen JB Overdiagnosis in malignant melanoma: a scoping review BMJ Evidence-Based Medicine 2024;29:17-28.Cramb SM, Duncan EW, Aitken JF, Soyer HP, Mengersen KL, Baade PD. Geographical patterns in melanoma incidence across Australia: Can thickness differentials reveal the key drivers? Ann Cancer Epidemiol 2020;4:11Daniel Lindsay, Katy J L Bell, Catherine M Olsen, David C Whiteman, Thanya Pathirana, Louisa G Collins, Estimating the magnitude and healthcare costs of melanoma in situand thin invasive melanoma overdiagnosis in Australia British Journal of Dermatology, 2024;191(6): 906–913,Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA Dermatol.2023;159(7):703–710. Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.

In this episode, we explore how melanoma risk prediction tools are transforming clinical decision-making for newly diagnosed patients. These tools, developed by Melanoma Institute Australia and freely available at melanomarisk.org.au, help clinicians tailor care and improve outcomes. Our multidisciplinary experts provide practical guidance on using tools to predict sentinel node metastasis, recurrence risk and more. Through real-world case examples and expert insights, this episode offers valuable strategies for integrating personalised risk assessment into your practice. This podcast is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals. Resources: Melanoma Risk Prediction CalculatorsMIA's Patient ResourcesMelanoma Education Portal Speakers: Prof Anne Cust - Cancer Epidemiologist and Faculty Member, Melanoma Institute Australia | Interim Director, Daffodil Centre | Chair, Cancer Council National Skin Cancer Committee A/Prof Alex Varey - Plastic and Reconstructive Surgeon, Melanoma Institute Australia and Westmead Hospital | Clinical Associate Professor, The University of Sydney A/Prof Linda Martin - Director of Dermatology Services, Melanoma Institute Australia | Staff Specialist, Sydney Children’s Hospital | Associate Professor of Dermatology, University of NSW Please note that this podcast was accurate at the time of recording (August 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE.

In this episode of Melanoma Insights for Professionals, we explore the evolving role of sentinel node biopsy (SNB) in melanoma management—particularly in the modern context of perioperative drug therapy. Our expert panel unpacks current evidence, shifting guidelines and real-world clinical considerations influencing when and why SNB is performed. Topics include prognostic value, surgical decision-making, pathological assessment, patient-centred perspectives and the impact of new treatment approaches on traditional staging practices. This podcast is produced by Melanoma Institute Australia and is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals. RESOURCES: Melanoma Risk Prediction Tools Patient brochure on SNB MIA's Melanoma Education Portal (Clinicians only) SPEAKERS: A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of SydneyA/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of SydneyA/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of SydneyDr Robert Rawson - Pathologist, Melanoma Institute Australia |Tissue Pathology Staff Specialist, Royal Prince Alfred Hospital Please note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.

In this episode of Melanoma Insights for Professionals, we explore the cutting-edge role of artificial intelligence (AI) in diagnosing melanoma. Join Dermatologists Prof Pascale Guitera and Prof Victoria Mar and Pathologist Dr Nigel Mayer as they unpack how AI is transforming clinical practice—from lesion detection and triage to deep learning in pathology and improving clinical education. Discover the promise, limitations and ethical considerations of integrating AI into dermatology and pathology, and hear what's next on the horizon for both clinicians and patients. This podcast is suitable for multidisciplinary specialists, primary care physicians, researchers and other healthcare professionals. SPEAKERS Prof Pascale Guitera - Dermatologist and Education Committee Chair, Melanoma Institute Australia | Director, Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital Prof Victoria Mar - Director, Victorian Melanoma Service at The Alfred | Professor of DermatoOncology, the School of Public Health and Preventive Medicine, Monash UniversityDr Nigel Maher - Pathologist, Melanoma Institute Australia | Chair of the AI Working Group, Royal College of Pathologists of Australasia Please note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from BMS, MSD and HEINE. For more practice-changing clinical education, visit the Melanoma Education Portal.

In this special podcast recorded from the 2024 Australasian Melanoma Conference, we hear from our international keynote speakers, Prof Susan Swetter and Prof Olivier Michelin, about what excites them in the field of melanoma research. Interviewed by AMC2024 Co-Chairs, Prof Georgina Long AO and Prof Richard Scolyer AO, our guests provide their multidisciplinary perspectives and highlight the importance of working together to make an impact in melanoma prevention and patient care. Dermatologist Prof Swetter discusses the evolving role of AI in dermatology and the clinical diagnosis of melanoma, and highlights the opportunity for improved prevention strategies in the US to reduce the incidence of melanoma. Prof Michelin explores how we’re tackling advanced melanoma, in particular to maximize our current treatment tools and manage drug toxicities. He also discusses expanding access to neoadjuvant therapies and the potential of TIL therapies, alongside AI advancements in histopathological diagnosis to personalise treatment approaches. This podcast is suitable for multidisciplinary healthcare professionals and researchers. SPEAKERS Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney |2024 Joint Australian of the Year Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney |2024 Joint Australian of the Year Prof Susan Swetter - Professor of Dermatology, Co-Director of the Pigmented Lesion/Melanoma and Cutaneous Oncology Programs, Stanford University Medical Center and Cancer Institute | Chair, National Comprehensive Cancer Network Melanoma Panel Prof Olivier Michelin - Chair, Department of Oncology and the Precision Oncology Service, Geneva University Hospital | Co-Director, Swiss Cancer Centre Léman| Vice-Coordinator, Translational Research Centre in Onco-Hematology Please note that this podcast was accurate at the time of recording (October 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Comprehensive infrastructure is essential to driving research progress and improving patient care. In this podcast, A/Prof Sydney Ch’ng leads an insightful discussion on the groundbreaking research infrastructure that underpins the many groundbreaking achievements at Melanoma Institute Australia. The discussion highlights the Institute’s clinical trial program, translational research, biospecimen bank and melanoma research database, offering a closer look at the critical elements driving progress. This podcast is suitable for multidisciplinary healthcare professionals, researchers and clinical trials staff. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof Serigne Lo - Senior Biostatistician, Melanoma Institute Australia | Associate Professor of Biostatistics, The University of Sydney Maria Gonzalez - Director of Clinical Care, Melanoma Institute Australia Dr Nicole Caixeiro - Head of the Biospecimen Bank, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (August 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. LINKS 2024 Australasian Melanoma Conference Melanoma Education Program MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Biomarkers are revolutionising our understanding of melanoma by providing valuable information about a patient's unique tumour characteristics which can help guide clinical decision making. In this podcast, A/Prof Alex Menzies leads a multidisciplinary discussion on the current state of biomarker application and future prospects of biomarkers in melanoma care. They discuss emerging liquid biomarkers, such as ctDNA, MIA’s personalised immunotherapy platform that is trying to predict the likelihood of response and select patients for treatment, and the role of the gut microbiome as a potential biomarker in response and toxicity. This podcast from Melanoma Institute Australia is suitable for Medical Oncologists, Surgical Oncologists, Researchers, GPs and other healthcare professionals. LINKS: 2024 Australasian Melanoma Conference Melanoma Risk Prediction Tools Melanoma Education Portal SPEAKERS A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Ines Silva - Medical Oncologist, Melanoma Institute Australia and Blacktown Hospital | Research Scientist, Melanoma Institute Australia and The University of Sydney Prof Helen Rizos - Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia A/Prof James Wilmott - Senior Scientist, Charles Perkins Centre, The University of Sydney| Faculty Member, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (April 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch’ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. Register now to attend the 2024 Australasian Melanoma Conference, hosted by Melanoma Institute Australia. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Raewyn Campbell - Rhinologist and Anterior Skull Base Surgeon |Associate Professor, Macquarie University Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Diagnostic uncertainty in the context of cutaneous melanoma can have significant impact on patient care. In this podcast, our multidisciplinary experts, led by Dr Adrian Quek, discuss the challenges faced in classifying melanocytic lesions that fall into a diagnostic grey area, and explore the terminology, evolving classifications and the impact of diagnostic uncertainty on patient outcomes. From molecular changes to clinical perspectives, this engaging discussion provides a comprehensive exploration of the complexities surrounding borderline lesions, and emphasises the need for experienced multidisciplinary professionals in ensuring accurate diagnoses and ideal management. This podcast is suitable for Pathologists, Dermatologists, Surgeons, Oncologists, GPs and other healthcare professionals. Register now to attend the ⁠2024 Australasian Melanoma Conference⁠, hosted by Melanoma Institute Australia. RESOURCES Video: How to diagnose borderline cutaneous melanocytic lesions Paper: Yeh, I. New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology. 2020;33:1-14. Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?. Arch Pathol Lab Med. 2011;135(3): 300–306. SPEAKERS Dr Adrian Quek - Skin Cancer GP, Melanoma Institute Australia and Chatswood Skin Cancer Clinic A/Prof Robyn Saw - General Surgeon, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney Prof H. Peter Soyer - Chair in Dermatology and Director of the Dermatology Research Centre, The University of Queensland Dr Andrew Colebatch - Staff Specialist in Anatomical Pathology, Royal Prince Alfred Hospital Please note that this podcast was accurate at the time of recording (November 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. For more clinical education from MIA, sign up to the Melanoma Education Portal.

With the advent of effective medical therapies for melanoma, a pertinent question has arisen: When should we scan our patients? In this podcast, our multidisciplinary experts, led by A/Prof Sydney Ch’ng, discuss the balance of whether we should be more aggressive in our pursuit of identifying potential metastases or exercise caution to avoid unnecessary scans, radiation exposure and patient anxiety. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, GPs, Oncology Nurses and other healthcare professionals. RESOURCES Melanoma Risk Prediction Tools SPEAKERS A/Prof Sydney Ch’ng -  Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia, Associate Professor of Surgery, The University of Sydney  A/Prof Alexander Menzies -  Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney Dr Edward Hsiao - Radiologist and Nuclear Medicine Specialist, Mater Imaging Dr Kevin London - Nuclear Medicine Specialist, The Children’s Hospital at Westmead | Clinical Senior Lecturer, The University of Sydney Please note that this podcast was accurate at the time of recording (September 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss: the history of SNB in the management of melanoma its current role in the stratification of patients into those who may benefit from adjuvant therapies verses those for whom active surveillance is more appropriate other potential benefits of SNB, including the likelihood of SNB itself reducing the risk of nodal recurrence. This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS A/Prof Sydney Ch’ng - Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Senior Surgeon, Melanoma Institute Australia Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Our latest podcast explores the innovative approach of neoadjuvant  immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of  melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential  benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: the benefits of checkpoint inhibitor immunotherapy the role of the pathologist in the assessment of neoadjuvant tissue the impact of surgical decision-making as neoadjuvant becomes mainstay treatment options for treatment-refractory patients the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer. The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists,  Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other  healthcare professionals. SPEAKERS: Prof Georgina Long AO - Co-Medical Director,  Melanoma Institute Australia | Chair, Melanoma Medical Oncology and  Translational Research, Melanoma Institute Australia and Royal North  Shore Hospital, The University of Sydney Prof Richard Scolyer AO - Co-Medical Director,  Melanoma Institute Australia | Pathologist, Melanoma Institute  Australia, Senior Staff Specialist, Royal Prince Alfred Hospital |  Clinical Professor, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist,  Melanoma Institute Australia, Royal North Shore and Mater Hospitals |  Associate Professor of Melanoma Medical Oncology, The University of  Sydney A/Prof Alexander van Akkooi - Associate Professor  in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal  Prince Alfred Hospital, The University of Sydney KEY CLINICAL TRIALS SWOG PRADO OpACIN-neo NADINA FURTHER EDUCATION The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists  Please note that this podcast was accurate at the time of recording  (February 2023) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary  discussion to unravel our understanding of the pathology, diagnosis and  management of lentigo maligna, including: clinical and histological presentation tools to diagnose and monitor lesions the impact of different types of biopsies the importance of mapping the extent of lesions the challenge of surgical management in cosmetically sensitive areas the role of radiation therapy and topical treatments when to refer your patient. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons,  Dermatologists, Oncologists, Pathologists, GPs, Nurses and other  healthcare professionals. SPEAKERS Dr Michael Rtshiladze - Plastic and Reconstructive  Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The  Prince of Wales Hospital, St George Hospital and Sydney Children’s  Hospital Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Prof Pascale Guitera - Dermatologist, Melanoma  Institute Australia | Director, Sydney Melanoma Diagnostic Centre at  Royal Prince Alfred Hospital | Professorial Research Fellow, The  University of Sydney Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney RESOURCE AND REFERENCE Lentigo Maligna Patient Information Brochure Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151. Please note that this podcast was accurate at the time of recording  (December 2022) but may not reflect the rapidly evolving treatment  landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.